Publicacions
-
Sánchez-Torres AM, Moreno-Izco L, Lorente-Omeñaca R, Cabrera B, Lobo A, González-Pinto AM, Merchán-Naranjo J, Corripio I, Vieta E, de la Serna E, Butjosa A, Contreras F, Sarró S, Mezquida G, Ribeiro M, Bernardo M, Cuesta MJ and PEPs group.
Individual trajectories of cognitive performance in first episode psychosis: a 2-year follow-up study.
European archives of psychiatry and clinical neuroscience . 268(7): 699-711. Nº de cites: 26
-
Ballesteros A, Sánchez-Torres AM, López-Ilundain JM, Cabrera B, Lobo A, González-Pinto AM, Díaz-Caneja C, Corripio I, Vieta E, de la Serna E, Bobes J, Usall J, Contreras F, Lorente-Omeñaca R, Mezquida G, Bernardo M, Cuesta MJ and PEPs Group.
Is cognitive impairment associated with antipsychotic dose and anticholinergic equivalent loads in first-episode psychosis?
PSYCHOLOGICAL MEDICINE . 48(13): 2247-2256. Nº de cites: 39
-
Lores L, Monje A, MANUEL BERGADA SALVADO, Arellano E, Rodriguez-Larrea J and Miravitlles M.
Prevalence of smoking in a psychiatric hospital and its relationship with respiratory symptoms and the prevalence of COPD.
INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE . 13: 2797-2804. Nº de cites: 10
-
Lacasa F, Álvarez M, Navarro MÁ, Richart MT, San L and Ortiz EM.
Emotion Regulation and Interpersonal Group Therapy for Children and Adolescents Witnessing Domestic Violence: A Preliminary Uncontrolled Trial.
Journal of Child & Adolescent Trauma . 11(3): 269-275. Nº de cites: 6
-
Paipa N, Stephan-Otto C, Cuevas-Esteban J, Araceli Núñez Navarro, Usall J and Brebion G.
Second-to-fourth digit length ratio is associated with negative and affective symptoms in schizophrenia patients.
SCHIZOPHRENIA RESEARCH . 199: 297-303. Nº de cites: 12
-
Alonso-Solís A, Rubinstein K, Corripio I, Jaaskelainen E, Seppälä A, Vella VA, Caro-Mendivelso J, Caspi A, Isohanni M, Unoka Z, Van der Graff S, Farkas K, Huerta-Ramos ME, Marcó-García S, Stevens M, Coenen T, Hospedales M, Berdún J, m-Resist group and Grasa EM.
Mobile therapeutic attention for treatment-resistant schizophrenia (m-RESIST): a prospective multicentre feasibility study protocol in patients and their caregivers.
BMJ Open . 8(7): . Nº de cites: 8
-
Soria V, González-Rodríguez A, Huerta-Ramos ME, Usall J, Cobo J, Bioque M, Barbero JD, García-Rizo C, Tost M, Monreal JA, PNECAT Group and Labad J.
Targeting hypothalamic-pituitary-adrenal axis hormones and sex steroids for improving cognition in major mood disorders and schizophrenia: a systematic review and narrative synthesis.
PSYCHONEUROENDOCRINOLOGY . 93: 8-19. Nº de cites: 51
-
San L, Estrada G, Oudovenko N, Montañés F, Dobrovolskaya N, Bukhanovskaya O, Popov M and Vieta E.
PLACID study: A randomized trial comparing the efficacy and safety of inhaled loxapine versus intramuscular aripiprazole in acutely agitated patients with schizophrenia or bipolar disorder.
EUROPEAN NEUROPSYCHOPHARMACOLOGY . 28(6): 710-718. Nº de cites: 19
-
Feliu A, Pérez A, Andrés L, Butjosa A, Díaz NS, Trujols J, Nuñez C, Stephan-Otto C, Rozadilla-Sacanell A, Serrano-Blanco A, Kratz A and Luciano JV.
Digging into the construct of fibrofog: Psychometric properties of the Spanish version of the Multidimensional Inventory of Subjective Cognitive Impairment in patients with fibromyalgia
Journal Of Applied Biobehavioral Research . 23(2): 1-22. Nº de cites: 8
-
Cortés MJ, Orejuela C, Castellví G, Folch A, Rovira L, Salvador-Carulla L, Irazábal M, Muñoz S, Haro JM, Vilella E and Martínez-Leal R.
Psychometric Properties of Spanish Adaptation of the PDD-MRS Scale in Adults with Intellectual Developmental Disorders: The EVTEA-DI Scale.
JOURNAL OF AUTISM AND DEVELOPMENTAL DISORDERS . 48(5): 1566-1578. Nº de cites: 5